Trial Profile
A phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Chlorambucil (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi Oncology
- 05 Nov 2007 Results published in Journal of Clinical Oncology.
- 30 Oct 2006 Status change
- 10 Oct 2006 Status change